Diabetes market set to increase with new drug introductions
WALTHAM, Mass. The launch and uptake of more than 20 new drugs to treat Type 2 diabetes will increase the market’s size by more than $12 billion, according to a report announced Tuesday.
In the United States, the United Kingdom, France, Germany, Spain, Italy and Japan over the next 10 years, novel and existing DPP-IV inhibitors and GLP-1 analogues, such as Merck & Co.’s Januvia (sitagliptin) and Onglyza (saxagliptin) by Bristol-Myers Squibb and AstraZeneca, are expected to increase the market size by $12.5 billion, research firm Decision Resources said in its report, titled “Type 2 Diabetes.”
The report noted that DPP-IV inhibitors have a low risk of hypoglycemia and a good tolerability profile, making them suitable for widespread use, while GLP-1 analogues are good for obese people with Type 2 diabetes.
“The commercial potential for drugs with demonstrated disease-modifying capabilities and long-term efficacy is reflected in the burgeoning pipeline for Type 2 diabetes, which currently has more than 400 drugs in active development,” Decision Resources analyst Christine Helliwell said. “However, with a greater regulatory burden in the United States and an increasingly crowded market, the barriers for success are higher than ever before.”
The report comes a day after the Pharmaceutical Research and Manufacturers of America released a report showing a record 183 diabetes drugs in clinical testing or awaiting Food and Drug Administration approval.
Bartell Drugs sponsors ‘Stock the Pantry’ food drive
SEATTLE Bartell Drugs has announced its sponsorship of its “Stock the Pantry” food drive to benefit a local food bank.
The regional chain said it would accept donations of nonperishable food for the organization Northwest Harvest at its 55 stores in the Seattle area from June 1 to 14.
The drive is designed to benefit families that depend on free or reduced-price school lunches during the summer months, when they may struggle to provide those meals at home.
FDA tenatively approves Teva pink eye generic
ROCKVILLE, Md. The Food and Drug Administration has given tentative approval to Teva Pharmaceutical Industries for its generic version of a drug for eye infections, FDA records showed.
The agency gave Teva the tentative approval for its moxifloxacin hydrochloride ophthalmic solution in the 0.5% strength. The solution is a generic version of Alcon’s Vigamox, which is used to treat bacterial conjunctivitis, commonly known as pink eye.
Alcon does not list the sales figures for Vigamox, though it reported sales of drugs to treat infections and inflammations of $882.5 million for 2008 in Securities and Exchange Commission filings.